The ANeED study - ambroxol in new and early dementia with Lewy bodies (DLB)
Currently, there are no disease-modifying pharmacological treatment options for dementia with Lewy bodies (DLB). The ANeED study is an ongoing clinical drug trial with ambroxol, aiming to investigate the tolerability, safety and effects of ambroxol in patients with DLB.
This is a multicentre, phase IIa, double-blinded, randomised and placebo-controlled clinical trial, using a parallel arm design for 18 months' follow-up.. The unique, but not fully understood mechanism of ABX on the enhancement of lysosomal aS clearance may be promising as a possible modifying treatment in DLB.
Trial registration: The clinical trial is registered in the international trials register - clinicaltrials.com (NCT0458825) and nationally at the Current Research Information System in Norway (CRISTIN 2235504).
The study is coordinated by Professor Arvid Rongve, Helse Fonna HF. SESAM/SUH is a participating centre.
Contact
If you are interested and want to know more, or would you like to participate in the research project, you can send an email to: sesamforskning@sus.no, or call our study phone: 51 51 29 47, or mobile phone 90 79 92 85.